Insiders who bought US$82.3k worth of Regulus Therapeutics Inc.'s ( NASDAQ:RGLS ) stock at an average buy price ...

Shares of Regulus Therapeutics ( RGLS, Financials) fell 24% to $0.89 as of 12:39 p.m. GMT-5 on Wednesday following the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regulus (RGLS – Research Report) and Roche ...

Regulus Therapeutics Inc (RGLS) stock saw a decline, ending the day at $0.97 which represents a decrease of $-0.20 or -17.09% from the prior close of $1.17. The stock opened at $1.08 and touched a low ...

Regulus Therapeutics (NASDAQ:RGLS) shares tumbled 24% Wednesday after the biotech company reported results from a study analysis for its ADPKD program and issued a regulatory update. Regulus ...

Regulus Therapeutics Inc . (NASDAQ:RGLS) stock has reached a new 52-week low, touching down at $1.16. This latest price ...

(RTTNews) - Regulus Therapeutics Inc. (RGLS) Wednesday announced positive clinical as well as regulatory updates from its autosomal dominant polycystic kidney disease (ADPKD) program.

Regulus Therapeutics Inc.’s RGLS share price has dipped by 17.09%, which has investors questioning if this is right time to ...

Exciting February sky events include Venus at its brightest and closest to Earth, the moon occulting the Pleiades, and a parade of planets in the post-sunset sky.

Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...